WHAT IS
GLIOBLASTOMA (GBM)?
Glioblastoma is a WHO Grade 4 astrocytoma β a malignant tumour arising from astrocytes in the brain that grows rapidly, infiltrates surrounding tissue, and recurs despite aggressive treatment. Understanding its biology and the modern treatment landscape is essential for patients and families navigating this diagnosis.
analyticsAt a Glance
- check_circleGBM accounts for ~50% of all malignant primary brain tumours β approximately 250,000 new cases globally per year
- check_circleMedian survival with optimal treatment (Stupp protocol): 14β16 months; 5-year survival <10%
- check_circleTwo key molecular biomarkers β IDH mutation status and MGMT methylation β determine prognosis and guide treatment decisions
- check_circleEmerging therapies include TTFields (Optune), immunotherapy, CAR-T, oncolytic viruses, and targeted agents based on molecular profiling
What Is Glioblastoma and How Does It Differ from Other Brain Tumours?
Glioblastoma β formally classified as WHO Grade 4 astrocytoma (IDH-wildtype) in the 2021 WHO Classification of Tumours of the CNS β arises from astrocytes, the star-shaped glial support cells of the brain. Unlike most solid tumours, GBM does not form a clean capsule β its cells infiltrate diffusely along white matter tracts, making complete surgical removal impossible and explaining its relentless recurrence even after aggressive treatment.
βGlioblastoma is not one disease β it is a collection of molecularly distinct tumours that share an aggressive growth pattern. Two patients with 'GBM' can have completely different molecular profiles, prognoses, and treatment responses. Molecular testing is not optional β it is the foundation of modern GBM management.β
Primary vs Secondary GBM
Primary (de novo) GBM arises without a prior lower-grade tumour β accounts for ~95% of GBM cases; predominantly IDH-wildtype; rapid onset; found in older adults (median age 64). Secondary GBM progresses from a lower-grade astrocytoma (Grade 2 or 3) over years β accounts for ~5% of cases; predominantly IDH-mutant; slower evolution; found in younger patients (median age 45). IDH mutation status is the key distinguishing biomarker.
Why GBM Is So Difficult to Treat
Three biological features make GBM uniquely challenging: (1) Diffuse infiltration β tumour cells spread millimetres to centimetres beyond visible MRI margins into functionally critical brain; (2) the blood-brain barrier (BBB) β limits systemic drug delivery to brain tissue; (3) intratumoral heterogeneity β different cells within the same tumour have different molecular profiles, enabling resistance to emerge from subclones that survive treatment.
GBM Molecular Subtypes and Their Significance
The 2021 WHO CNS classification replaced purely histological GBM grading with a molecularly integrated framework β the most important update to GBM diagnosis in decades.
| Molecular Subtype | Frequency | Key Features | Prognosis |
|---|---|---|---|
| IDH-wildtype GBM (WHO Grade 4) | ~95% of GBM cases | TERT promoter mutation; EGFR amplification; +7/β10 chromosomal pattern; typically primary de novo; older patients | Median OS 14β16 months with Stupp protocol; MGMT methylation improves prognosis within this group |
| IDH-mutant astrocytoma, Grade 4 | ~5% of GBM | IDH1 or IDH2 point mutation; CDKN2A/B homozygous deletion; secondary progression from lower-grade tumour; younger patients | Significantly better prognosis β median OS 24β48 months; IDH inhibitors (vorasidenib) now emerging as targeted option |
| MGMT-methylated GBM (IDH-wildtype) | ~40β45% of IDH-wildtype GBM | Promoter methylation silences MGMT DNA repair enzyme β sensitises tumour to temozolomide | Best prognosis within IDH-wildtype β benefit from temozolomide is most pronounced; median OS 18β22 months in optimal cohorts |
| MGMT-unmethylated GBM | ~55β60% of IDH-wildtype GBM | MGMT enzyme active β repairs temozolomide-induced DNA damage; limited TMZ benefit | Worse prognosis β median OS 12β14 months; temozolomide less effective; need for alternative or experimental strategies |
| EGFR-amplified GBM | ~40β50% of GBM | EGFR amplification Β± EGFRvIII mutation; targetable in principle but anti-EGFR drugs have failed to date | No proven targeted therapy yet; EGFRvIII-directed CAR-T and bispecifics in trials |
| H3K27-altered diffuse midline glioma | Distinct entity β not GBM | H3K27M mutation; brainstem/thalamic location; now classified separately from GBM | Very poor β median OS 9β14 months; ONC201 (dordaviprone) showed activity in H3K27M-mutant cases |
Symptoms, Diagnosis, and the Route to a GBM Diagnosis
GBM is typically diagnosed after a rapid-onset clinical presentation β the speed of symptom evolution distinguishes it from lower-grade tumours.
- 1
Presenting Symptoms
Headache (particularly morning headache that improves through the day β from overnight ICP rise), focal neurological deficits (weakness, speech difficulty, visual field deficits depending on tumour location), new-onset seizures (25β30% of patients at presentation), and cognitive or personality changes. Symptoms typically evolve over weeks rather than months β the rapid course is characteristic of GBM.
- 2
Urgent MRI Brain with Contrast
The standard diagnostic imaging β contrast-enhanced MRI shows GBM as a ring-enhancing mass with central necrosis and surrounding oedema (FLAIR/T2 hyperintensity). The ring enhancement represents disruption of the blood-brain barrier at the tumour margin. Advanced MRI sequences (perfusion, spectroscopy, diffusion) add characterisation but are not required for the initial diagnosis.
- 3
Stereotactic Biopsy or Surgical Resection
Tissue diagnosis is required β no imaging pattern is diagnostic without histopathology. Surgical resection (craniotomy) provides both diagnosis and maximum safe resection. For tumours in eloquent cortex or deep structures where resection is unsafe, stereotactic needle biopsy provides tissue without open surgery. Intraoperative MRI and fluorescence-guided surgery (5-ALA) improve resection extent.
- 4
Neuropathology and Molecular Testing
The surgical specimen undergoes integrated histological and molecular analysis: IDH1/2 mutation (IHC Β± sequencing), MGMT promoter methylation (pyrosequencing), EGFR amplification and EGFRvIII mutation (FISH/PCR), TERT promoter mutation, 1p/19q codeletion (distinguishes oligodendroglioma from astrocytoma), and H3K27M mutation for midline tumours. This molecular panel takes 1β3 weeks and defines the final WHO classification.
- 5
Multidisciplinary Team Review
Before any treatment decision is made, the case should be reviewed at a neuro-oncology MDT including a neurosurgeon, radiation oncologist, medical oncologist, neuroradiologist, and neuropathologist. The MDT review confirms the WHO classification, reviews the extent of resection, and agrees on the treatment plan β typically beginning with radiation + temozolomide (Stupp protocol) within 4β6 weeks of surgery.
GBM vs Other Brain Tumours: Key Differences That Matter for Treatment
GBM is frequently confused with other brain tumour types β the differences in biology, prognosis, and treatment are profound.
Glioblastoma (WHO Grade 4)
- Median OS 14β16 months with standard treatmentDespite decades of research, the median survival with surgery + radiation + temozolomide has improved only marginally since the Stupp trial in 2005.
- Always recurs β no curative standard treatment100% recurrence rate after standard treatment β GBM should be understood as a disease where treatment extends and improves quality of life but rarely eliminates all disease.
- Diffuse infiltration β no clear surgical marginGBM cells infiltrate centimetres beyond the visible contrast-enhancing tumour β there is no clean resection margin, and residual infiltrating cells inevitably give rise to recurrence.
- Rapid clinical course β symptoms evolve in weeksThe speed of clinical deterioration in GBM is qualitatively different from lower-grade tumours β requiring urgent diagnosis and rapid treatment initiation.
Lower-Grade Gliomas / Other Tumours
- Oligodendroglioma (IDH-mutant, 1p/19q-codeleted)Median OS >10β15 years with treatment; chemosensitive to PCV and temozolomide; typically younger patients; long treatment windows.
- IDH-mutant astrocytoma Grade 2β3Median OS 5β15 years depending on grade and molecular features; IDH inhibitors (vorasidenib) now approved for adult IDH-mutant glioma.
- Meningioma (WHO Grade 1)Generally benign β surgery is usually curative; median OS measured in decades; most patients cured with resection alone.
- Brain metastasesNot primary brain tumours β treated differently from GBM; stereotactic radiosurgery and systemic therapy determined by primary cancer biology.
Glioblastoma: Key Clinical Numbers
Reference figures that frame the clinical landscape of GBM.
- 14β16 moMedian OS with Stupp protocol (surgery + RT + TMZ + adjuvant TMZ)Established by the landmark Stupp et al. NEJM 2005 trial β still the reference benchmark for all subsequent GBM trials.
- <10%5-year overall survival rate for IDH-wildtype GBMDespite numerous trial efforts since 2005, the 5-year survival rate remains below 10% for the majority of GBM patients β reflecting the intractable resistance mechanisms of this tumour.
- 40β45%Of IDH-wildtype GBM are MGMT-methylated β the most actionable prognostic subgroupMGMT methylation significantly improves TMZ response and survival β identifying this subgroup before treatment starts is essential for prognosis and decisions about alkylating chemotherapy.
- 64 yrsMedian age at GBM diagnosisGBM predominantly affects older adults β age is an independent prognostic factor; elderly patients (>70) have worse outcomes and modified treatment protocols (hypofractionated RT Β± TMZ).
More from the Glioblastoma Resource Library
Continue exploring glioblastoma β from molecular testing and the Stupp protocol to emerging treatments.
- β Glioblastoma β Complete Guide
- IDH Mutation in Brain Tumours: What It Means and Why It Matters
- MGMT Methylation Testing: Why It Is Essential Before GBM Treatment
- The Stupp Protocol: Surgery, Radiation, and Temozolomide for GBM
- Tumour Treating Fields (TTFields/Optune): How It Works
- GBM at Recurrence: Treatment Options After First Progression
Frequently Asked Questions
Common questions from patients and families newly diagnosed with glioblastoma.
Understanding GBM
Is glioblastoma always fatal?
Glioblastoma is the most aggressive primary brain tumour, and the vast majority of patients do not achieve long-term survival with current standard treatment. However, 'always fatal' is not accurate β approximately 5β10% of patients with GBM survive beyond 5 years, and a small cohort of exceptional long-term survivors has been documented in the literature. These long-term survivors disproportionately have MGMT-methylated tumours, younger age at diagnosis, and excellent performance status. Whether differences in tumour biology, host immune response, or treatment factors explain long-term survival is an active area of research. The honest answer is that GBM is a disease with very poor median survival, but meaningful individual variation exists.
How quickly does glioblastoma grow?
GBM is among the fastest-growing primary tumours β its doubling time is measured in days to weeks rather than months. The period from first symptoms to diagnosis is typically 1β3 months for most patients, and untreated GBM grows rapidly enough to cause life-threatening neurological deterioration within weeks of diagnosis. This is why GBM is treated as an oncological urgency β surgery within days of diagnosis where possible, followed by radiation and chemotherapy within 4β6 weeks. The rapid growth rate is also why recurrence after treatment is almost universal β the residual infiltrating cells that survive treatment are the seeds of recurrence, which typically occurs within 6β8 months of completing initial treatment.
My MRI shows a ring-enhancing lesion β does this definitely mean GBM?
A ring-enhancing lesion on MRI is a characteristic pattern strongly associated with GBM but is not specific to it. Other conditions that can produce ring-enhancing lesions include: brain metastases (the most common ring-enhancing brain lesion overall), brain abscess, tumefactive multiple sclerosis, lymphoma, and radiation necrosis after previous radiotherapy. The only definitive diagnosis of GBM is from histopathology and molecular analysis of a tissue sample obtained by biopsy or resection. No imaging pattern alone is diagnostic. If you have received a 'likely GBM' or 'ring-enhancing lesion' finding on MRI, neurosurgical referral for tissue diagnosis is the essential next step.
Does glioblastoma run in families?
The vast majority of GBM cases are sporadic β approximately 95% have no identifiable hereditary cause. A small proportion (<5%) are associated with rare hereditary syndromes: Li-Fraumeni syndrome (TP53 germline mutation), neurofibromatosis type 1 (NF1), Lynch syndrome (mismatch repair gene mutations), and BRCA1/2-associated pathways. If you have a strong family history of brain tumours or multiple early-onset cancers across generations, genetic counselling is appropriate. For most patients, GBM is an acquired sporadic event without implications for family members' cancer risk.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Navigating a Glioblastoma Diagnosis?
CancerFax connects GBM patients and families with specialist neuro-oncologists in China and India β reviewing your molecular profiling (IDH, MGMT, EGFR), imaging, and prior treatment to assess all available options including clinical trials, TTFields access, and emerging therapies.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.